Sprint Bioscience
Market Cap
kr197.1m
Last Updated
2019/08/21 21:45 UTC
Data Sources
Company Financials
Executive Summary
Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism.
Snowflake
Fundamentals
Mediocre balance sheet and overvalued.
Risks
- Sprint Bioscience has significant price volatility in the past 3 months.
- Sprint Bioscience is not covered by any analysts.
Share Price & News
How has Sprint Bioscience's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
13.4%
OM:SPRINT
2.5%
SE Biotechs
2.2%
SE Market
1 Year Return
10.8%
OM:SPRINT
-18.5%
SE Biotechs
-2.1%
SE Market
SPRINT outperformed the Biotechs industry which returned -18.9% over the past year.
SPRINT outperformed the Market in Sweden which returned -2.3% over the past year.
Share holder returns
| SPRINT | Industry | Market | |
|---|---|---|---|
| 7 Day | 13.4% | 2.5% | 2.2% |
| 30 Day | 5.3% | -7.9% | -3.4% |
| 90 Day | 22.8% | -2.0% | 0.5% |
| 1 Year | 10.8%10.8% | -18.1%-18.5% | 2.0%-2.1% |
| 3 Year | -55.4%-55.4% | 42.2%31.2% | 24.9%6.4% |
| 5 Year | n/a | 54.2%53.6% | 45.2%14.5% |
Price Volatility Vs. Market
How volatile is Sprint Bioscience's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Is Sprint Bioscience AB (publ)'s (STO:SPRINT) CEO Being Overpaid?2 months ago | Simply Wall St
How Does Investing In Sprint Bioscience AB (publ) (STO:SPRINT) Impact The Volatility Of Your Portfolio?3 months ago | Simply Wall St
Do Directors Own Sprint Bioscience AB (publ) (STO:SPRINT) Shares?Valuation
Is Sprint Bioscience undervalued based on future cash flows and its price relative to the stock market?
3.62x
Price to Book (PB) ratio
Intrinsic Value Based on Future Cash Flows
Unable to calculate intrinsic value for Sprint Bioscience to establish if it is available at moderate discount.
Unable to calculate intrinsic value for Sprint Bioscience to establish if it is available at substantial discount.
Price Based on Earnings
Sprint Bioscience is loss making, we can't compare its value to the SE Biotechs industry average.
Sprint Bioscience is loss making, we can't compare the value of its earnings to the Sweden market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Sprint Bioscience, we can't assess if its growth is good value.
Price Based on Value of Assets
Sprint Bioscience is good value based on assets compared to the SE Biotechs industry average.
Next Steps
Future Growth
How is Sprint Bioscience expected to perform in the next 1 to 3 years based on estimates from 0 analysts?
12.5%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sprint Bioscience has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Take a look at our analysis of SPRINT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Sprint Bioscience competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has Sprint Bioscience performed over the past 5 years?
-13.9%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Sprint Bioscience does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Sprint Bioscience's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Sprint Bioscience's 1-year growth to the SE Biotechs industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Sprint Bioscience has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Sprint Bioscience has efficiently used its assets last year compared to the SE Biotechs industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Sprint Bioscience improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Sprint Bioscience's financial position?
Financial Position Analysis
Sprint Bioscience is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Sprint Bioscience's long term commitments exceed its cash and other short term assets.
Debt to Equity History and Analysis
Sprint Bioscience has no debt.
Sprint Bioscience has no debt compared to 5 years ago when it was 73.5%.
Balance Sheet
Low level of unsold assets.
Sprint Bioscience has no debt, it does not need to be covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Sprint Bioscience has less than a year of cash runway based on current free cash flow.
Sprint Bioscience has less than a year of cash runway if free cash flow continues to grow at historical rates of 72.3% each year.
Next Steps
Dividend
What is Sprint Bioscience's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Sprint Bioscience's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Sprint Bioscience's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Sprint Bioscience has not reported any payouts.
Unable to verify if Sprint Bioscience's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Sprint Bioscience has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of Sprint Bioscience's salary, the management and board of directors tenure and is there insider trading?
5.6yrs
Average management tenure
CEO
Jessica Martinsson (47yo)
0.2yrs
Tenure
Ms. Jessica Martinsson, MSc Co-founded Sprint Bioscience AB in February 2009 and serves as its Acting Chief Executive Officer since June 11, 2019 and serves as its Head of Operations until June 11, 2019. M ...
Management Age and Tenure
5.6yrs
Average Tenure
52.5yo
Average Age
The average tenure for the Sprint Bioscience management team is over 5 years, this suggests they are a seasoned and experienced team.
Board Age and Tenure
1.3yrs
Average Tenure
63yo
Average Age
The average tenure for the Sprint Bioscience board of directors is less than 3 years, this suggests a new board.
Insider Trading
No 3 month open market individual insider trading information.
Ownership Breakdown
Management Team
Anders Åberg (61yo)
Founder & Senior Adviser
- Tenure: 10.6yrs
- Compensation: kr1.32m
Pär Nordlund (61yo)
- Tenure: 0.0yrs
- Compensation: kr25.00k
Martin Andersson (48yo)
Founder & Head of Research
- Tenure: 10.6yrs
Jessica Martinsson (47yo)
Founder & Acting CEO
- Tenure: 0.2yrs
Kenth Hallberg (48yo)
Founder & Director of Structural Chemistry
- Tenure: 0.0yrs
Anne-Marie Wenthzel
Head of Business Development
- Tenure: 0.0yrs
Karin Liwendahl (57yo)
Chief Financial Officer
- Tenure: 0.6yrs
Board Members
Rune Nordlander (63yo)
Chairman
- Tenure: 9.6yrs
- Compensation: kr167.00k
Charlotta Liljebris
Director
- Tenure: 2.3yrs
- Compensation: kr58.00k
Fredrik Lehman (43yo)
Director
- Tenure: 0.3yrs
Jan-Erik Nyström (66yo)
Director
- Tenure: 0.3yrs
Company Information
Sprint Bioscience AB (publ)'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sprint Bioscience AB (publ)
- Ticker: SPRINT
- Exchange: OM
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr197.087m
- Shares outstanding: 11.63m
- Website: https://www.sprintbioscience.com
Location
- Sprint Bioscience AB (publ)
- Novum
- Hälsovägen 7, 8th floor
- Huddinge
- Stockholm County
- 141 57
- Sweden
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SPRINT | OM (OMX Nordic Exchange Stockholm) | Yes | Share Capital | SE | SEK | Nov 2014 |
Biography
Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism. It engages in developing STK25, a drug candidate against a new target protein for the treatment of type 2 ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/08/21 21:45 |
| End of Day Share Price | 2019/08/21 00:00 |
| Earnings | 2019/03/31 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.